Chronic Neuropathic Pain

Adil Abbasi MD

Management of Chronic Neuropathic Pain

Introduction and Background

Chronic neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system, affecting either peripheral or central structures (Treede et al., 2008). Unlike nociceptive pain, which results from injury to non-neural tissue and is usually self-limited, neuropathic pain persists and is often more resistant to standard treatments. It is estimated that up to 10% of people experience neuropathic pain at some point, making it a major public health concern (van Hecke et al., 2014; Finnerup et al., 2015). This type of pain contributes to significant impairment in physical functioning, mental health, and overall quality of life (Moulin et al., 2014).

Because of its multifaceted origins and complex pathophysiology, management is best approached using a patient-centered, multimodal framework that combines medication, physical and psychological therapies, and, when needed, interventional procedures (NICE, 2020).

Bulleted Summary:

Neuropathic pain results from nerve injury/disease.
Affects up to 10% of the population.
Causes major disability and impaired quality of life.
Requires a multidisciplinary, multimodal management plan.

Pathophysiology and Etiology

Neuropathic pain arises from abnormal signaling in the nervous system after nerve injury, inflammation, or disease. Peripheral sensitization increases nociceptor excitability, while central sensitization amplifies pain signals in the spinal cord (Jensen et al., 2011). Dysfunction of inhibitory interneurons and maladaptive plasticity contribute to persistent symptoms. Ectopic discharges, increased sodium/calcium channel expression, and neuroinflammatory responses (including glial activation and cytokine release) further sustain the pain state.

Common etiologies include diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, radiculopathy, phantom limb pain, and central post-stroke pain (Finnerup et al., 2015; NICE, 2020).

Bulleted Summary:

Key mechanisms: peripheral and central sensitization, loss of inhibition, maladaptive plasticity.
Contributing factors: ectopic discharges, channel upregulation, neuroinflammation.
Common causes: diabetes, shingles, nerve compression, stroke, phantom limb.

Clinical Assessment

Diagnosis is primarily clinical, based on characteristic history and physical findings. Patients may describe burning, shooting, stabbing, electric shock-like, or tingling pain (Dworkin et al., 2013). Examination often reveals sensory deficits (e.g., numbness), allodynia (pain from non-painful stimuli), hyperalgesia (increased response to pain), and sometimes trophic skin changes.

Validated tools like the DN4, painDETECT, and LANSS questionnaires can increase diagnostic accuracy (Freynhagen et al., 2006). A neuroanatomical pain distribution and an identifiable lesion or disease support the diagnosis (Treede et al., 2008).

Bulleted Summary:

Diagnosis is clinical, supported by screening tools (DN4, painDETECT, LANSS).
Key symptoms: burning, shooting, electric pain, allodynia, hyperalgesia.
Examination: sensory loss, abnormal sensations, skin/tissue changes.
Look for plausible neuroanatomical distribution and underlying cause.

Principles of Management

The primary goal is not complete pain elimination, but meaningful pain reduction, better function, and improved quality of life (Finnerup et al., 2015). Management should address the biological, psychological, and social dimensions of pain. Patient education is essential for setting realistic expectations and supporting adherence (Moulin et al., 2014).

A multimodal approach is strongly recommended, combining medications, physical rehabilitation, psychological therapies, and interventional treatments when needed (NICE, 2020).

Bulleted Summary:

Aim for pain reduction and improved function—not cure.
Multimodal care addresses physical, psychological, and social needs.
Patient education and realistic expectations are critical.
Interdisciplinary care improves outcomes.

Pharmacologic Management

First-Line Medications

1. Tricyclic Antidepressants (TCAs)

Amitriptyline and nortriptyline are effective by inhibiting norepinephrine and serotonin reuptake, enhancing descending pain inhibition (Saarto & Wiffen, 2007). Side effects (anticholinergic, sedative, cardiac) can limit use in elderly or those with cardiac risks.

2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Duloxetine and venlafaxine offer similar efficacy with fewer side effects, especially suitable for elderly or patients with cardiac issues. Duloxetine is FDA-approved for diabetic neuropathy (Finnerup et al., 2015).

3. Gabapentinoids

Gabapentin and pregabalin block calcium channels, reducing neurotransmitter release. Particularly effective in diabetic neuropathy and postherpetic neuralgia (Moore et al., 2014). Pregabalin is preferred for rapid titration.

All first-line drugs should be started at low doses and titrated upward based on efficacy and tolerability (Finnerup et al., 2015).

Bulleted Summary:

TCAs: effective, but sedating and anticholinergic.
SNRIs: similar efficacy, better tolerated; duloxetine FDA-approved.
Gabapentinoids: best for diabetic and postherpetic neuropathy.
Start low, titrate slow for all first-line agents.

Second-Line and Adjunctive Agents

4. Topical Medications

Lidocaine 5% patch is useful for localized pain (e.g., postherpetic neuralgia) and is well tolerated (Baron et al., 2009). High-dose (8%) capsaicin patch can provide long-term relief after a single clinic-based application, though it can be uncomfortable during placement (Finnerup et al., 2015).

5. Other Anticonvulsants

Carbamazepine is first-line for trigeminal neuralgia, but less used for other types due to side effects. Oxcarbazepine and lamotrigine have less evidence, sometimes used off-label (Wiffen et al., 2014).

Bulleted Summary:

Lidocaine patch: safe, effective for localized neuropathic pain.
Capsaicin 8% patch: long-term relief, can cause transient discomfort.
Carbamazepine: drug of choice for trigeminal neuralgia.

Third-Line Agents

6. Opioids and Tramadol

Reserved for severe, refractory cases due to dependence and limited long-term efficacy (Finnerup et al., 2015; Moulin et al., 2014). Tramadol has additional SNRI effects.

7. Specialty Agents

NMDA antagonists (e.g., ketamine infusions) and botulinum toxin injections are options for highly refractory cases under specialist care.

Bulleted Summary:

Opioids: use only for refractory cases; high risk for side effects.
Tramadol: may be tried for breakthrough pain.
NMDA antagonists and botulinum toxin: specialist use only.

General Pharmacologic Principles

Start low, go slow to minimize adverse effects.
Monitor for drug interactions and cumulative toxicity.
Reassess for efficacy and tolerability; discontinue ineffective agents.
Combination therapy sometimes used, but evidence is limited.

Bulleted Summary:

Careful titration and monitoring are essential.
Polypharmacy increases risk of interactions.
Ongoing reassessment and adjustment optimize outcomes.

Non-Pharmacologic and Multidisciplinary Approaches

Physical Therapy and Rehabilitation:
Graded exercise, stretching, and desensitization help preserve function and reduce pain-related disability. Occupational therapy supports activities of daily living (NICE, 2020).

Psychological Therapies:
CBT, ACT, and mindfulness improve coping, reduce distress, and address comorbid depression or anxiety (Eccleston et al., 2014).

Complementary and Integrative Therapies:
Acupuncture, TENS, yoga, and meditation may provide benefit for select patients, though evidence varies (Johnson et al., 2015).

Patient Education:
Teach pacing, energy conservation, and realistic goal setting to empower patients in self-management.

Bulleted Summary:

Physical therapy: preserves mobility and reduces deconditioning.
CBT and mindfulness: treat psychological contributors to pain.
TENS, acupuncture: adjunctive benefit in select patients.
Education: helps set expectations and fosters self-management.

Interventional and Advanced Approaches

For patients unresponsive to standard treatments, interventional procedures can be considered (Dworkin et al., 2013; Simpson et al., 2021):

Nerve blocks: Peripheral or ganglion blocks for focal neuropathies.
Neuromodulation:

Spinal cord stimulation (SCS): strong evidence for failed back surgery syndrome and complex regional pain syndrome (Simpson et al., 2021).
Peripheral nerve/dorsal root ganglion stimulation: focal pain syndromes.

Intrathecal drug delivery: Rarely for neuropathic pain alone; considered in complex, refractory cases.

Bulleted Summary:

Consider nerve blocks for focal pain.
SCS: best evidence for certain syndromes.
Interventional options are specialist-driven and for refractory cases.

Special Populations and Considerations

Elderly: More sensitive to side effects; favor topical and non-drug therapies.
Psychiatric comorbidity: Integrate psychological treatment for optimal results (Finnerup et al., 2015).
Diabetes: Glycemic control is important, but may not eliminate pain.
Pediatric patients: Age-appropriate adaptation required.

Bulleted Summary:

Lower doses and topical/non-drug therapies for elderly.
Integrated care for psychiatric comorbidities.
Address underlying conditions as part of overall management.

Drug Comparisons for Neuropathic Pain

Table 1. First-Line Pharmacologic Agents

Drug/Class	Mechanism	Starting Dose	Titration/Target Dose	Onset of Effect	Common Side Effects	Key Indications	Clinical Pearls
Amitriptyline (TCA)	Inhibits NE/5-HT reuptake	10–25 mg qHS	25–100 mg qHS	2–4 weeks	Sedation, dry mouth, constipation, weight gain, orthostasis	Most neuropathic pain, insomnia	Avoid in elderly/heart disease; titrate slowly
Nortriptyline (TCA)	As above, less anticholinergic	10–25 mg qHS	25–100 mg qHS	2–4 weeks	As above, less sedating	As above	Safer than amitriptyline in elderly
Duloxetine (SNRI)	Inhibits NE/5-HT reuptake	30 mg qAM	60–120 mg daily (qAM or divided)	1–2 weeks	Nausea, dry mouth, sweating, hypertension, sexual dysfunction	Diabetic neuropathy, fibromyalgia, depression	Monitor BP; caution in liver/renal dysfunction
Venlafaxine XR (SNRI)	As above	37.5 mg qAM	75–225 mg daily (divided)	1–2 weeks	Nausea, insomnia, hypertension	General neuropathic pain	BP monitoring required
Gabapentin	Binds α2δ Ca channels	100–300 mg qHS	1200–3600 mg/day (divided TID)	1–2 weeks	Sedation, dizziness, edema, ataxia	Diabetic/postherpetic neuropathy	Titrate every 3–7 days; renal dosing
Pregabalin	As above, better bioavailability	50 mg BID	150–600 mg/day (BID-TID)	1–2 weeks	As above, weight gain	As above	Faster titration; some abuse potential

qHS: every night at bedtime; qAM: every morning; BID: twice daily; TID: three times daily

Table 2. Second-Line & Adjunctive Agents

Drug/Class	Mechanism	Dose/Regimen	Main Side Effects	Indications	Clinical Pearls
Lidocaine 5% Patch	Na+ channel block	Apply 12h on/12h off (max 3 patches)	Local rash, rare systemic	Localized neuropathic pain (PHN)	Well-tolerated, minimal systemic effect
Capsaicin 8% Patch	TRPV1 agonist	In-clinic, 60-min single application	Burning, erythema, discomfort	Localized neuropathic pain	Painful to apply, prolonged benefit
Carbamazepine	Na+ channel block	100 mg BID, up to 1200 mg/day	Dizziness, hyponatremia, leukopenia, rash	Trigeminal neuralgia	Screen for HLA-B*1502 (Asians); monitor CBC, LFTs
Oxcarbazepine, Lamotrigine	As above	Variable (see guidelines)	Rash, hyponatremia	Refractory neuropathic pain	Less evidence, off-label use
Tramadol	Weak opioid/SNRI	50–100 mg q6h PRN (max 400 mg/day)	Sedation, nausea, constipation, dependence	Refractory pain	Caution with serotonin syndrome, seizures

Table 3. Third-Line/Specialist Agents

Drug/Class	Dosing/Regimen	Indications	Major Caveats/Clinical Pearls
Strong opioids	Morphine, oxycodone, etc.	Severe, refractory pain	High dependence, overdose risk, last resort
NMDA antagonists	Ketamine infusions	Refractory neuropathic pain	Specialist use only; psychotropic side effects
Botulinum toxin	Local injection	Localized focal pain	Only for selected focal neuropathies

Clinical Pearls for Neuropathic Pain Management

Start Low, Go Slow: Particularly in elderly or frail patients, slow titration reduces side effects and improves adherence.
Polypharmacy Risks: Many patients require multiple agents. Always check for drug–drug interactions, especially with TCAs and other CNS depressants.
Antidepressants Double-Duty: Use SNRIs or TCAs in patients with both neuropathic pain and comorbid depression/anxiety for additional benefit.
Gabapentinoid Monitoring: Adjust dosing in renal impairment. Watch for sedation, especially if combined with opioids or CNS depressants.
Topical Agents: Particularly valuable in frail/elderly or polypharmacy patients. Minimal systemic exposure and side effects.
Education is Key: Set realistic goals—aim for improved function and quality of life, not “zero pain.”
Comorbidities: Depression, anxiety, insomnia, and disability are common. Always screen and treat these in parallel.
Red Flags: Sudden neurological deficits, bowel/bladder dysfunction, or progressive weakness should prompt urgent evaluation for a structural cause.
Refer Early for Interventions: For severe, focal, or refractory pain, early referral improves outcomes and avoids unnecessary drug escalation.
Document Baseline and Progress: Track pain scores, function, and quality of life at each visit for objective assessment.

References:

Baron R, Binder A, Wasner G. Efficacy and safety of 5% lidocaine medicated plaster in localized neuropathic pain: Review of the clinical data. Pain. 2009;146(3):195-204.
Dworkin RH, Backonja M, Rowbotham MC, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3-14.
Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the diagnosis and management of neuropathic pain: An overview and literature update. Mayo Clin Proc. 2013;88(5):507-517.
Eccleston C, Palermo TM, Williams AC, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2014;(5):CD003968.
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.
Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: A new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911-1920.
Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204-2205.
Johnson M, Martinson M. Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain: A meta-analysis. Pain. 2015;156(11):2094-2101.
Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;(4):CD007938.
Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-335.
National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in non-specialist settings. Clinical guideline [CG173]. 2013 (updated 2020).
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;(4):CD005454.
Simpson EL, Duenas A, Holmes MW, Papaioannou D, Chilcott J. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: Systematic review and economic evaluation. Health Technol Assess. 2021;23(60):1-305.
Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630-1635.
van Hecke O, Torrance N, Smith BH. Prevalence and characteristics of neuropathic pain in the general population: A systematic review. Pain. 2014;155(4):654-662.
Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;(4):CD005451.